
1. transfusion. 1995 jul;35(7):548-51.

the canadian hemophilia registry basis national system for
monitoring use factor concentrates.

walker i(1), pai m, akabutu j, ritchie b, growe g, poon mc, card r, ali k,
israels s, teitel j, et al.

author information: 
(1)association hemophilia clinic directors canada, toronto, ontario.

comment in
    transfusion. 1996 jan;36(1):86-87.

background: canada's publicly funded blood system recently introduced
high-purity concentrates standard treatment individuals with
hemophilia. added cost need document patient outcomes have
prompted consideration national blood product monitoring system.
study design methods: study investigates suitability canadian
hemophilia registry (chr) basis monitoring system assessing
the degree represents users factor concentrates.
results: currently, 1978 individuals registered chr, whom
1594 (81%) hemophilia 384 (19%) hemophilia b. total
prevalence 7.2 per 10(5) population, prevalence severe cases being
2.3 per 10(5). overall prevalence similar seen countries
with national registries. chr national prevalence also compares favorably
with province quebec, registration users blood
products compulsory. chr figures indicate number persons
currently infected human immunodeficiency virus, alive dead, is
652, similar number applicants (658) federal
government's assistance program. registry stable, number of
persons severe cases, young children, newly registered lost to
follow-up last 2 years small.
conclusion: chr includes vast majority factor concentrate users is
therefore ideal basis national monitoring system.

doi: 10.1046/j.1537-2995.1995.35795357875.x 
pmid: 7631385  [indexed medline]

